FIND YOUR CONSULTANT
JOIN OUR COMMUNITY
FIND YOUR CONSULTANT
JOIN OUR COMMUNITY
Resources >

Life Sciences Industry Acronyms >

Vaccines, Biologics & Cell/Gene Therapy Industry Acronyms

Vaccines, Biologics & Cell/Gene Therapy Industry Acronyms

Receive consulting resources in your inbox

This glossary highlights specialized acronyms used across the Life Sciences sector in vaccine development, biologics manufacturing, and advanced therapies. It helps executives and practitioners navigate the regulatory, clinical, quality, safety, supply-chain, and technical language central to the Vaccines, Biologics & Cell/Gene Therapy Practice.

A B C D E F G H I J L M N O P Q R S T U V W X Z

A
AAV Adeno-Associated Virus:
A small, nonpathogenic virus widely engineered as a vector for delivering therapeutic genes to target tissues.
ACIP Advisory Committee on Immunization Practices:
A U.S. federal advisory committee that develops recommendations for vaccine use, schedules, dosing, and eligible populations.
ADA Anti-Drug Antibody:
An immune response against a therapeutic protein that may affect exposure, efficacy, safety, or clinical interpretation.
ADC Antibody-Drug Conjugate:
A targeted biologic that links an antibody to a cytotoxic or other active payload for delivery to cells expressing a selected antigen.
ADCC Antibody-Dependent Cellular Cytotoxicity:
An Fc-mediated mechanism in which immune effector cells kill antibody-coated target cells, often evaluated for therapeutic antibodies and vaccine-induced responses.
ADCP Antibody-Dependent Cellular Phagocytosis:
An Fc-mediated process in which phagocytes ingest antibody-coated cells or particles, providing a functional measure of antibody activity.
AE Adverse Event:
Any unfavorable medical occurrence after administration of a medicinal product, whether or not a causal relationship has been established.
AEFI Adverse Event Following Immunization:
A medical occurrence observed after vaccination that requires assessment to determine seriousness, expectedness, and possible causality.
AESI Adverse Event of Special Interest:
A prespecified safety outcome requiring targeted monitoring because of biological plausibility, prior evidence, or regulatory concern.
AEX Anion-Exchange Chromatography:
A charge-based separation technique used in biologics purification to remove impurities or separate product variants.
AMC Advance Market Commitment:
A financing mechanism that guarantees future demand or funding to encourage development and supply of vaccines for defined public-health needs.
APR Annual Product Review:
A periodic assessment of manufacturing, quality, deviations, complaints, and process performance used to confirm that a product remains in control.
APS Aseptic Process Simulation:
A media-fill exercise used to demonstrate that an aseptic manufacturing process can consistently prevent microbial contamination.
ASO Antisense Oligonucleotide:
A short synthetic nucleic-acid sequence designed to alter RNA processing, stability, or translation for therapeutic effect.
ASTCT American Society for Transplantation and Cellular Therapy:
A professional organization whose consensus criteria and guidance are widely used for cellular-therapy practice and toxicity management.
ATMP Advanced Therapy Medicinal Product:
The European regulatory category covering gene therapies, somatic cell therapies, tissue-engineered products, and certain combined products.
B
BARDA Biomedical Advanced Research and Development Authority:
A U.S. government authority that funds and supports development, manufacturing, and procurement of vaccines and other medical countermeasures.
BCG Bacillus Calmette–Guérin:
A live attenuated vaccine used primarily against tuberculosis and also employed as an immunotherapy in selected clinical settings.
BET Bacterial Endotoxins Test:
A compendial quality-control test used to detect and quantify pyrogenic endotoxins in parenteral products and manufacturing materials.
BFS Blow-Fill-Seal:
An automated aseptic process that forms, fills, and seals a plastic container in one continuous operation.
BLA Biologics License Application:
The U.S. submission through which a sponsor seeks authorization to market a biological product based on evidence of safety, purity, potency, and manufacturing control.
bsAb Bispecific Antibody:
An engineered antibody capable of binding two different antigens or epitopes, enabling mechanisms such as immune-cell redirection or dual-pathway blockade.
BSC Biosafety Cabinet:
A ventilated enclosure that protects personnel, products, and the environment during handling of biological materials.
BSE Bovine Spongiform Encephalopathy:
A transmissible spongiform encephalopathy considered in sourcing and risk assessment for animal-derived raw materials used in biological manufacturing.
BSL Biosafety Level:
A graded containment classification defining facility, equipment, and work-practice controls for handling biological agents of differing risk.
BTD Breakthrough Therapy Designation:
A U.S. regulatory designation intended to expedite development and review of therapies showing substantial improvement over available treatment for serious conditions.
C
CAPA Corrective and Preventive Action:
A quality-system process for identifying root causes, correcting detected problems, and preventing recurrence or occurrence elsewhere.
CAR Chimeric Antigen Receptor:
An engineered receptor that combines antigen recognition with intracellular signaling to redirect immune cells against selected targets.
CAR-T Chimeric Antigen Receptor T-Cell Therapy:
A cellular therapy in which T cells are genetically modified to recognize and attack cells expressing a defined antigen.
CAT Committee for Advanced Therapies:
The European Medicines Agency committee responsible for scientific assessment and classification of advanced therapy medicinal products.
CBER Center for Biologics Evaluation and Research:
The U.S. Food and Drug Administration center that regulates vaccines, blood products, allergenics, and cellular and gene therapies.
CCI Cold Chain Indicator:
A monitoring device that signals whether a temperature-sensitive product may have experienced unacceptable storage or transport conditions.
CCID50 50% Cell Culture Infectious Dose:
An infectivity measure representing the amount of virus required to infect half of inoculated cell cultures under defined assay conditions.
CCIT Container Closure Integrity Testing:
Testing that verifies a vial, syringe, or other package maintains a sterile barrier and protects product quality throughout shelf life.
CCS Contamination Control Strategy:
A coordinated framework for controlling microbial, particulate, and other contamination risks across facilities, processes, personnel, and materials.
CDC Centers for Disease Control and Prevention:
The U.S. public-health agency responsible for disease surveillance, outbreak response, immunization guidance, and vaccine-safety programs.
CDC Complement-Dependent Cytotoxicity:
An antibody effector mechanism in which complement activation leads to lysis or damage of an antibody-bound target cell.
CDR Complementarity-Determining Region:
A variable antibody-domain sequence that largely determines antigen-binding specificity and is central to antibody engineering and characterization.
CEPI Coalition for Epidemic Preparedness Innovations:
A global partnership that finances and coordinates vaccine development for emerging infectious diseases and epidemic threats.
CE-SDS Capillary Electrophoresis–Sodium Dodecyl Sulfate:
An analytical method used to assess protein size, purity, fragmentation, and aggregation under reducing or nonreducing conditions.
CEX Cation-Exchange Chromatography:
A charge-based purification or analytical method frequently used to separate biologics from impurities and resolve charge variants.
cGMP Current Good Manufacturing Practice:
Regulations and quality principles governing controlled, consistent manufacture and testing of medicinal products.
cGTP Current Good Tissue Practice:
U.S. requirements intended to prevent communicable-disease transmission through human cells, tissues, and cellular and tissue-based products.
CHMP Committee for Medicinal Products for Human Use:
The European Medicines Agency committee that evaluates human medicines and issues scientific opinions on marketing authorization.
CHO Chinese Hamster Ovary:
A mammalian cell platform widely used to produce recombinant antibodies and other therapeutic proteins.
cIEF Capillary Isoelectric Focusing:
An analytical technique that separates proteins by isoelectric point and supports characterization of charge heterogeneity.
CIOMS Council for International Organizations of Medical Sciences:
An international organization whose guidance and reporting frameworks influence pharmacovigilance, benefit-risk assessment, and clinical research ethics.
CIP Clean-in-Place:
Automated cleaning of process equipment without disassembly, used to achieve repeatable sanitation in manufacturing systems.
CMA Critical Material Attribute:
A raw-material or input characteristic that must remain within suitable limits to ensure process performance and product quality.
CMC Chemistry, Manufacturing, and Controls:
The regulatory information describing product composition, manufacturing processes, analytical controls, facilities, and quality assurance.
CoA Certificate of Analysis:
A controlled document reporting specifications, test methods, and results for a material, intermediate, or finished-product lot.
CoC Chain of Custody:
The documented record of possession, handling, transfer, and storage of patient material or product throughout an advanced-therapy workflow.
COI Chain of Identity:
The controls that maintain an unbroken link between a patient, collected starting material, manufactured therapy, and final administration.
CPP Critical Process Parameter:
A process variable whose variation can affect a critical quality attribute and therefore requires monitoring or control.
CPV Continued Process Verification:
Ongoing collection and evaluation of process data to confirm that commercial manufacturing remains in a validated state.
CQA Critical Quality Attribute:
A physical, chemical, biological, or microbiological property that must remain within appropriate limits to ensure product quality.
CQV Commissioning, Qualification, and Validation:
The lifecycle activities used to demonstrate that facilities, utilities, equipment, and processes are fit for intended use.
CRISPR Clustered Regularly Interspaced Short Palindromic Repeats:
The basis of programmable genome-editing systems used to add, remove, or modify genetic sequences in therapeutic development.
CRS Cytokine Release Syndrome:
A potentially serious systemic inflammatory response associated particularly with T-cell-engaging biologics and engineered cellular therapies.
CRT Controlled Room Temperature:
A defined pharmaceutical storage range maintained and monitored to protect product stability during warehousing and distribution.
CTA Clinical Trial Application:
A regulatory submission seeking authorization to conduct a clinical trial in jurisdictions using this application pathway.
CTC Controlled Temperature Chain:
An approved approach allowing certain vaccines to be kept outside the traditional cold chain for a limited period under monitored conditions.
CTD Common Technical Document:
The internationally harmonized structure used to organize quality, nonclinical, and clinical information in medicinal-product submissions.
CTL Cytotoxic T Lymphocyte:
An immune cell capable of recognizing and killing infected, malignant, or otherwise targeted cells.
D
DMC Data Monitoring Committee:
An independent group that reviews accumulating clinical-trial data and advises whether a study should continue, change, or stop.
DMSO Dimethyl Sulfoxide:
A cryoprotective agent commonly used during freezing of therapeutic cells, requiring control because residual exposure can affect patients and products.
DNA Deoxyribonucleic Acid:
The hereditary molecule used as a therapeutic payload, vector component, template, or analytical target in genetic medicines.
DoE Design of Experiments:
A structured statistical approach for evaluating multiple process variables and their interactions during development and optimization.
DP Drug Product:
The finished dosage form containing the active biological material and suitable for storage, distribution, and administration.
dPCR Digital Polymerase Chain Reaction:
A partition-based nucleic-acid assay used for sensitive absolute quantification of vector genomes, copy number, or residual sequences.
DS Drug Substance:
The active biological material manufactured before formulation, filling, and conversion into the finished dosage form.
DSMB Data and Safety Monitoring Board:
An independent committee that periodically reviews trial safety, efficacy, and conduct to protect participants and study integrity.
DSP Downstream Processing:
The recovery, purification, concentration, and formulation operations performed after biological production or cell culture.
DSUR Development Safety Update Report:
A periodic regulatory report that summarizes and evaluates safety information for an investigational medicinal product.
DTaP Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine:
A pediatric combination vaccine protecting against diphtheria, tetanus, and pertussis.
DTP Diphtheria-Tetanus-Pertussis Vaccine:
A combination vaccine and immunization-program indicator used to protect children against three major infectious diseases.
E
EC50 Half Maximal Effective Concentration:
The concentration producing 50% of the maximum measured biological response, often used in potency and functional assays.
ECDC European Centre for Disease Prevention and Control:
The European Union agency that supports infectious-disease surveillance, risk assessment, and vaccination policy.
eCTD Electronic Common Technical Document:
The standardized electronic format used to submit and maintain regulatory dossiers for medicinal products.
EDQM European Directorate for the Quality of Medicines & HealthCare:
The Council of Europe body responsible for the European Pharmacopoeia and related systems supporting medicine quality and biological standardization.
EEFO Earliest-Expiry-First-Out:
An inventory practice that prioritizes distribution and use of stock with the nearest expiry date to minimize wastage.
EID50 50% Egg Infectious Dose:
The quantity of virus required to infect half of inoculated embryonated eggs under defined test conditions.
ELISA Enzyme-Linked Immunosorbent Assay:
A plate-based method used to detect or quantify antibodies, antigens, host-cell proteins, and other biological analytes.
ELISpot Enzyme-Linked Immunospot:
A sensitive cellular assay that counts individual cells secreting a specific cytokine or antibody after stimulation.
EM Environmental Monitoring:
Routine sampling of air, surfaces, personnel, and utilities to assess contamination control in manufacturing areas.
EMA European Medicines Agency:
The European Union agency responsible for scientific evaluation, supervision, and safety monitoring of medicines.
EOPC End-of-Production Cells:
Cells sampled at or beyond the production limit and characterized to assess the continued safety and genetic stability of a manufacturing substrate.
EPI Expanded Programme on Immunization:
The World Health Organization framework supporting equitable access to routine vaccines and stronger national immunization systems.
ERA Environmental Risk Assessment:
An evaluation of potential environmental impacts associated with a medicinal product, including shedding or release of genetically modified organisms.
EUA Emergency Use Authorization:
A U.S. mechanism permitting temporary use of qualifying unapproved medical products, or unapproved uses, during a declared emergency.
EUL Emergency Use Listing:
A World Health Organization risk-based procedure for assessing unlicensed vaccines and other health products needed during public-health emergencies.
EVM Effective Vaccine Management:
A World Health Organization framework for assessing and improving vaccine supply chains, storage, distribution, and stock management.
F
Fab Fragment Antigen-Binding:
The antibody region containing the antigen-binding site, used in characterization and as a basis for engineered therapeutic fragments.
FACT Foundation for the Accreditation of Cellular Therapy:
An accreditation body that establishes quality standards for cellular therapy collection, processing, and clinical administration programs.
FBS Fetal Bovine Serum:
An animal-derived cell-culture supplement whose sourcing, variability, and adventitious-agent risks require careful control.
Fc Fragment Crystallizable:
The antibody region that interacts with immune receptors and complement, influencing effector function, distribution, and half-life.
FDA Food and Drug Administration:
The U.S. regulator responsible for authorizing and overseeing vaccines, biologics, cellular therapies, gene therapies, and related manufacturing facilities.
FIH First-in-Human:
The initial clinical administration of an investigational product to people, requiring careful dose selection and risk mitigation.
FMEA Failure Mode and Effects Analysis:
A structured risk-assessment method used to identify potential failures, evaluate their consequences, and prioritize controls.
G
GCP Good Clinical Practice:
The international ethical and scientific quality standard for designing, conducting, recording, and reporting clinical trials.
G-CSF Granulocyte Colony-Stimulating Factor:
A cytokine used clinically to stimulate blood-cell production and mobilize hematopoietic stem and progenitor cells for collection.
GDP Good Distribution Practice:
Quality requirements for maintaining product identity, integrity, traceability, and authorized storage conditions throughout distribution.
GLP Good Laboratory Practice:
Quality principles governing the organization, conduct, documentation, and reporting of nonclinical safety studies.
GMC Geometric Mean Concentration:
A summary measure commonly used for positively skewed antibody-concentration data in vaccine immunogenicity studies.
GMO Genetically Modified Organism:
An organism whose genetic material has been altered through biotechnology, triggering specific handling and environmental requirements in many jurisdictions.
GMP Good Manufacturing Practice:
The quality framework ensuring medicinal products are consistently produced and controlled to appropriate standards.
GMT Geometric Mean Titer:
A summary measure of antibody titers frequently used to compare immune responses across vaccine groups and time points.
gRNA Guide RNA:
An engineered RNA sequence that directs a genome-editing enzyme to a selected nucleic-acid target.
GTMP Gene Therapy Medicinal Product:
A European advanced-therapy category for products whose therapeutic effect depends on recombinant nucleic-acid sequences or their expression.
GVHD Graft-Versus-Host Disease:
A potentially severe immune complication in which donor-derived cells attack recipient tissues, relevant to allogeneic transplantation and cellular therapies.
H
HA Hemagglutinin:
A major influenza-virus surface glycoprotein and vaccine antigen involved in viral attachment to host cells.
HAU Hemagglutination Unit:
A measure of viral or antigen activity based on the ability to agglutinate red blood cells.
HAV Hepatitis A Virus:
The causative virus of hepatitis A and the antigenic target of inactivated and live attenuated vaccines.
HBsAg Hepatitis B Surface Antigen:
The principal antigen used in recombinant hepatitis B vaccines and a key marker in hepatitis B testing.
HBV Hepatitis B Virus:
A blood-borne virus targeted by preventive vaccines and considered in donor and starting-material screening.
HCP Host Cell Protein:
A process-related impurity originating from production cells that must be monitored and reduced during biologics purification.
HCT/P Human Cells, Tissues, and Cellular and Tissue-Based Products:
The U.S. regulatory category covering donated human materials intended for implantation, transplantation, infusion, or transfer.
HDR Homology-Directed Repair:
A cellular DNA-repair pathway used in genome editing to introduce precise sequence changes from a donor template.
HEK293 Human Embryonic Kidney 293:
A widely used cell line for research and production of viral vectors, recombinant proteins, and vaccine components.
HEPA High-Efficiency Particulate Air:
A filtration classification used in cleanrooms and containment systems to remove airborne particles from supplied or exhausted air.
HI Hemagglutination Inhibition:
An assay measuring antibodies that prevent virus-mediated agglutination of red blood cells, especially in influenza studies.
Hib Haemophilus influenzae Type b:
A bacterium targeted by conjugate vaccines that prevent invasive disease, particularly in young children.
HIV Human Immunodeficiency Virus:
A retrovirus relevant to vaccine research, donor screening, biosafety, and testing of human-derived starting materials.
HLA Human Leukocyte Antigen:
The human major histocompatibility system, important for immune recognition, patient matching, and cellular-therapy response or safety.
HLH Hemophagocytic Lymphohistiocytosis:
A severe hyperinflammatory syndrome that may arise independently or in association with immune-effector-cell therapies.
HPV Human Papillomavirus:
A group of viruses targeted by prophylactic vaccines to prevent cervical and other HPV-associated cancers and diseases.
HSC Hematopoietic Stem Cell:
A self-renewing cell capable of generating all blood-cell lineages and used as a starting material or therapeutic product.
HSPC Hematopoietic Stem and Progenitor Cell:
A broader blood-forming cell population frequently collected, genetically modified, and reinfused in ex vivo gene therapy.
HSV Herpes Simplex Virus:
A human virus that is also engineered as an oncolytic or gene-delivery vector after removal or modification of pathogenic functions.
I
ICANS Immune Effector Cell-Associated Neurotoxicity Syndrome:
A neurological toxicity associated with certain immune-effector-cell therapies that requires standardized grading and prompt management.
ICH International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use:
The international body that develops harmonized quality, safety, efficacy, and multidisciplinary guidelines for medicinal-product development.
ICSR Individual Case Safety Report:
A structured report describing a suspected adverse reaction in an individual patient for pharmacovigilance assessment and regulatory reporting.
IEC-HS Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome:
A severe hyperinflammatory toxicity recognized after immune-effector-cell treatment and distinguished from conventional cytokine release syndrome.
IFN Interferon:
A family of immune-signaling proteins involved in antiviral defense and frequently measured in vaccine and cellular immune-response studies.
IgG Immunoglobulin G:
The predominant antibody class in blood and a major form measured in vaccine immunogenicity and used in therapeutic antibodies.
IIS Immunization Information System:
A confidential population-based system that records vaccination histories and supports coverage monitoring, reminders, and program management.
IL-2 Interleukin-2:
A cytokine central to T-cell activation and expansion, used in immune monitoring and some cell-culture or therapeutic protocols.
IMPD Investigational Medicinal Product Dossier:
A European clinical-trial document containing quality, manufacturing, nonclinical, and clinical information about an investigational product.
IND Investigational New Drug Application:
The U.S. regulatory submission that permits clinical investigation of a new medicinal product when applicable requirements are met.
IPC In-Process Control:
A test, measurement, or check performed during manufacturing to monitor process status and support consistent product quality.
iPSC Induced Pluripotent Stem Cell:
A reprogrammed somatic cell capable of differentiating into many cell types and used as a platform for regenerative and engineered-cell therapies.
IPV Inactivated Poliovirus Vaccine:
A non-live vaccine containing inactivated poliovirus antigens and used in routine polio immunization programs.
ISCT International Society for Cell & Gene Therapy:
A professional society that develops consensus terminology, standards, and guidance for cell and gene therapy translation and manufacturing.
ITR Inverted Terminal Repeat:
A repeated sequence at the ends of certain viral genomes that is essential to vector replication, packaging, or persistence.
IVIG Intravenous Immunoglobulin:
A pooled plasma-derived antibody product used for immune replacement and immunomodulatory treatment.
J
JACIE Joint Accreditation Committee ISCT-Europe & EBMT:
A European accreditation program setting quality standards for hematopoietic-cell collection, processing, transplantation, and related cellular therapies.
L
LAF Laminar Airflow:
Unidirectional filtered airflow used to protect exposed sterile products and critical processing zones from contamination.
LAL Limulus Amebocyte Lysate:
A reagent derived from horseshoe-crab blood cells and used in established methods for detecting bacterial endotoxins.
LC-MS Liquid Chromatography–Mass Spectrometry:
A combined analytical technique used to characterize identity, structure, purity, modifications, and impurities in complex biological products.
LN2 Liquid Nitrogen:
A cryogenic medium used to store and transport cells, cell banks, and other temperature-sensitive biological materials.
LNP Lipid Nanoparticle:
A delivery system that encapsulates and protects nucleic acids while facilitating uptake into target cells.
LOD Limit of Detection:
The lowest amount or concentration of an analyte that an assay can reliably distinguish from background.
LOQ Limit of Quantification:
The lowest analyte level that an assay can measure with acceptable accuracy and precision.
LTFU Long-Term Follow-Up:
Extended safety monitoring used particularly for gene therapies to detect delayed adverse events, persistence effects, or secondary malignancies.
LTR Long Terminal Repeat:
A regulatory sequence at each end of a retroviral genome that influences integration and gene expression in vector systems.
LVV Lentiviral Vector:
An engineered retroviral delivery system commonly used for stable gene transfer into dividing and nondividing cells.
M
MAA Marketing Authorization Application:
A formal submission seeking regulatory approval to place a medicinal product on the market.
mAb Monoclonal Antibody:
An antibody derived from a single clone or engineered sequence and designed to bind a specific antigen or epitope.
MAH Marketing Authorization Holder:
The legal entity responsible for an approved medicine, including its quality, supply, labeling, and pharmacovigilance obligations.
MAS Macrophage Activation Syndrome:
A severe hyperinflammatory condition involving excessive immune activation and considered in the differential diagnosis of cellular-therapy toxicities.
MCB Master Cell Bank:
A well-characterized, uniform stock of production cells from which working cell banks and manufacturing cultures are derived.
MDCK Madin–Darby Canine Kidney:
A continuous cell line used in virology, influenza research, and production of certain cell-based influenza vaccines.
MDVP Multi-Dose Vial Policy:
World Health Organization guidance defining when opened multi-dose vaccine vials may be retained for later immunization sessions.
MedDRA Medical Dictionary for Regulatory Activities:
The standardized international terminology used to code and analyze adverse events, indications, and other medical information.
MHC Major Histocompatibility Complex:
A group of molecules that present antigens to T cells and shape immune recognition, compatibility, and therapeutic response.
MMR Measles, Mumps, and Rubella Vaccine:
A combined live attenuated vaccine used in routine childhood and adult immunization programs.
MN Microneutralization:
A cell-based assay used to quantify antibodies that inhibit viral infection or replication.
MNC Mononuclear Cell:
A blood or tissue cell with a single nucleus, including lymphocytes and monocytes, that may serve as cellular-therapy starting material.
MOA Mechanism of Action:
The biological process through which a product produces its intended effect, informing potency assays, development strategy, and regulatory evaluation.
MOI Multiplicity of Infection:
The ratio of infectious viral particles to target cells, used to control transduction or infection during process development.
mRNA Messenger RNA:
A transient nucleic-acid template that directs protein synthesis and serves as the active component of several vaccines and genetic medicines.
MSC Mesenchymal Stromal Cell:
A multipotent stromal-cell population investigated for regenerative, immunomodulatory, and tissue-repair applications.
MSL Master Seed Lot:
A characterized stock of virus or microorganism used to establish consistent working seeds for vaccine production.
MTD Maximum Tolerated Dose:
The highest tested dose associated with an acceptable level of toxicity under a defined clinical protocol.
MVA Modified Vaccinia Ankara:
A highly attenuated poxvirus strain used as a vaccine platform and viral vector for delivery of recombinant antigens.
MVM Minute Virus of Mice:
A small parvovirus used as a model challenge virus in clearance studies and monitored as an adventitious-agent risk in rodent cell substrates.
N
NAb Neutralizing Antibody:
An antibody that blocks infection or biological activity, serving as a key vaccine-response and biologic-immunogenicity measure.
NAT Nucleic Acid Testing:
Molecular testing used to detect viral or other genetic material in donors, starting materials, products, or environmental samples.
NCL National Control Laboratory:
A government laboratory that independently tests or reviews vaccine and biological-product lots to support official release and oversight.
NGS Next-Generation Sequencing:
High-throughput sequencing used for identity, genetic stability, integration-site, adventitious-agent, and genomic-editing analyses.
NHEJ Non-Homologous End Joining:
A cellular DNA-repair pathway that reconnects broken DNA ends and often creates insertions or deletions after genome editing.
NHP Nonhuman Primate:
A preclinical model used selectively to evaluate immunogenicity, biodistribution, efficacy, and safety where biologically justified.
NIP National Immunization Program:
A government program that plans, finances, procures, distributes, and monitors vaccines for eligible populations.
NITAG National Immunization Technical Advisory Group:
An independent expert body that provides evidence-based recommendations on vaccine policy and immunization schedules.
NK Natural Killer:
An innate immune-cell type capable of killing abnormal cells and increasingly used as a platform for engineered cellular therapies.
NRA National Regulatory Authority:
The government body responsible for regulating medicinal products, manufacturers, clinical trials, safety, and market authorization within a country.
O
OCABR Official Control Authority Batch Release:
A European system requiring independent assessment and, where applicable, testing of certain vaccine and biological-product batches before market release.
ODD Orphan Drug Designation:
A regulatory status for products targeting rare diseases that may provide development incentives and market benefits.
OOS Out of Specification:
A test result falling outside an approved acceptance criterion and requiring documented investigation and disposition.
OOT Out of Trend:
A result that remains within specification but differs unexpectedly from historical or anticipated process behavior.
OPV Oral Poliovirus Vaccine:
A live attenuated vaccine administered orally and used in polio-control and eradication programs.
ORF Open Reading Frame:
A nucleic-acid sequence capable of encoding a protein and commonly engineered into vaccine or gene-therapy constructs.
OTP Office of Therapeutic Products:
The U.S. Food and Drug Administration office within the biologics center that oversees cellular, gene, and related therapeutic products.
P
pAb Polyclonal Antibody:
A mixture of antibodies recognizing multiple epitopes, used in diagnostics, research reagents, antitoxins, and some therapeutic preparations.
PAHO Pan American Health Organization:
The specialized international health agency for the Americas, supporting immunization policy, procurement, surveillance, and disease control.
PAI Pre-Approval Inspection:
A regulatory inspection conducted before authorization to verify that manufacturing facilities, controls, and submitted information are reliable and compliant.
PAT Process Analytical Technology:
A framework for measuring and controlling manufacturing processes through timely analysis of critical material and process attributes.
PBMC Peripheral Blood Mononuclear Cell:
A mixed population of lymphocytes and monocytes used in immune assays, cell processing, and therapeutic manufacturing.
PBRER Periodic Benefit-Risk Evaluation Report:
A structured postauthorization report that evaluates cumulative safety information alongside benefits and important new evidence.
PCR Polymerase Chain Reaction:
A molecular technique that amplifies defined DNA sequences for identity, purity, safety, and diagnostic testing.
PCV Packed Cell Volume:
The fraction of a culture occupied by cells after settling or centrifugation, used as a biomass indicator in some production processes.
PCV Pneumococcal Conjugate Vaccine:
A vaccine linking pneumococcal polysaccharides to carrier proteins to produce stronger, longer-lasting immune responses, especially in young children.
PD Pharmacodynamics:
The study of a product’s biological effects and their relationship to dose or exposure.
PDUFA Prescription Drug User Fee Act:
U.S. legislation authorizing application fees that support regulatory review and establish performance goals for submissions, including biological products.
PEG Polyethylene Glycol:
A polymer used in formulations, lipid nanoparticles, and protein conjugation to influence stability, solubility, exposure, or delivery.
PFS Prefilled Syringe:
A ready-to-administer presentation that can improve dosing convenience while imposing specific compatibility, stability, and container-closure requirements.
PFU Plaque-Forming Unit:
A measure of infectious virus based on the number of visible plaques formed in a susceptible cell layer.
Ph. Eur. European Pharmacopoeia:
A legally recognized collection of quality standards and test methods for medicines, ingredients, biological products, and analytical procedures in Europe.
PIC/S Pharmaceutical Inspection Co-operation Scheme:
An international framework promoting harmonized manufacturing inspection standards and cooperation among participating regulatory authorities.
PK Pharmacokinetics:
The study of product absorption, distribution, persistence, metabolism, and elimination over time.
PMDA Pharmaceuticals and Medical Devices Agency:
The Japanese agency responsible for scientific review, safety measures, inspections, and consultation for medicines and biological products.
PPQ Process Performance Qualification:
Documented demonstration that a commercial manufacturing process can reproducibly deliver product meeting predetermined quality requirements.
PQS Performance, Quality and Safety:
The World Health Organization system for evaluating and prequalifying immunization-related cold-chain equipment and devices.
PRAC Pharmacovigilance Risk Assessment Committee:
The European Medicines Agency committee responsible for assessing and monitoring safety issues for human medicines.
PRNT Plaque Reduction Neutralization Test:
A functional assay that quantifies antibodies by measuring their ability to reduce virus plaque formation in cell culture.
PSUR Periodic Safety Update Report:
A postauthorization report summarizing worldwide safety data and evaluating whether the product’s benefit-risk profile has changed.
PUPSIT Pre-Use Post-Sterilization Integrity Testing:
Testing performed before filtration to confirm that a sterilized product filter remained integral after installation and sterilization.
PV Pharmacovigilance:
The detection, assessment, understanding, and prevention of adverse effects and other medicine-related safety problems.
Q
QbD Quality by Design:
A systematic development approach linking product and process understanding, risk management, and control strategy to predefined quality objectives.
QMS Quality Management System:
The integrated policies, processes, responsibilities, and records used to ensure compliant and consistent product quality.
QP Qualified Person:
The legally designated professional in European systems who certifies medicinal-product batches before release or export.
R
RABS Restricted Access Barrier System:
A physical and airflow barrier that reduces operator intervention and contamination risk in aseptic processing zones.
rcAAV Replication-Competent Adeno-Associated Virus:
An unintended viral form capable of replication under permissive conditions and therefore controlled as a gene-therapy product impurity.
RCL Replication-Competent Lentivirus:
An unintended replication-capable virus that must be assessed and controlled in lentiviral-vector manufacturing and treated-patient monitoring.
RCR Replication-Competent Retrovirus:
A safety concern arising when a replication-defective retroviral vector acquires the ability to propagate.
rDNA Recombinant Deoxyribonucleic Acid:
Genetic material created by joining sequences from different sources and used to produce therapeutic proteins, vaccines, and gene-therapy constructs.
RMAT Regenerative Medicine Advanced Therapy:
A U.S. expedited-program designation for qualifying regenerative medicines addressing serious conditions and supported by preliminary clinical evidence.
RMM Rapid Microbiological Method:
An alternative or automated technique designed to detect, quantify, or identify microorganisms faster than conventional culture methods.
RMP Risk Management Plan:
A regulatory document describing known and potential safety risks, missing information, pharmacovigilance activities, and risk-minimization measures.
RNA Ribonucleic Acid:
A nucleic acid serving as genetic material, therapeutic cargo, a regulatory molecule, or an intermediate in protein expression.
RNAi RNA Interference:
A cellular mechanism in which small RNA molecules suppress gene expression by targeting specific messenger RNA.
RP2D Recommended Phase 2 Dose:
The dose selected for further clinical evaluation based on safety, activity, pharmacology, and feasibility rather than toxicity alone.
RSV Respiratory Syncytial Virus:
A major respiratory pathogen targeted by vaccines and long-acting preventive antibodies, particularly for infants and older adults.
RT-PCR Reverse Transcription Polymerase Chain Reaction:
A molecular method that converts RNA into complementary DNA before amplification for detection or quantification.
RVLP Retrovirus-Like Particle:
A noninfectious particle produced by some cell substrates and monitored during characterization and viral-safety assessment.
S
SAE Serious Adverse Event:
An event meeting regulatory seriousness criteria such as death, life-threatening illness, hospitalization, disability, or congenital anomaly.
SAGE Strategic Advisory Group of Experts on Immunization:
The principal advisory group providing the World Health Organization with global policy recommendations on vaccines and immunization.
SAL Sterility Assurance Level:
The probability of a viable microorganism remaining on or in a product after a validated sterilization process.
saRNA Self-Amplifying RNA:
An engineered RNA platform that encodes both a target antigen or protein and machinery enabling intracellular RNA replication.
SC Subcutaneous:
A route of administration in which a product is injected into tissue beneath the skin.
SCR Seroconversion Rate:
The proportion of participants who develop a defined antibody response or qualifying increase from baseline after vaccination.
SEC Size-Exclusion Chromatography:
A separation method used to measure aggregates, fragments, and molecular-size distributions in biological products.
sgRNA Single-Guide RNA:
An engineered RNA molecule combining targeting and scaffold functions to direct a genome-editing nuclease.
SIN Self-Inactivating:
A viral-vector design in which regulatory elements are disabled after integration to reduce unintended transcriptional activity.
SIP Steam-in-Place:
In-situ sterilization of installed process equipment and piping using controlled steam exposure.
SISPQ Safety, Identity, Strength, Purity, and Quality:
Core product attributes considered in the regulatory assessment and control of biological products.
SmPC Summary of Product Characteristics:
The European regulator-approved document defining a medicine’s indications, dosing, contraindications, warnings, adverse reactions, and other prescribing information.
SMQ Standardised MedDRA Query:
A validated grouping of medical terms used to identify and analyze safety cases related to a defined medical condition or area of interest.
SOP Standard Operating Procedure:
An approved instruction describing how a recurring regulated activity must be performed and documented.
SPC Statistical Process Control:
The use of statistical methods and control charts to monitor process behavior, detect variation, and support continued process verification.
SPF Specific Pathogen Free:
A controlled biological status indicating that animals, eggs, or colonies are free from specified infectious agents.
SPR Seroprotection Rate:
The proportion of vaccinated participants whose antibody level meets a predefined threshold associated with protection.
SRID Single Radial Immunodiffusion:
An immunochemical assay traditionally used to quantify influenza hemagglutinin antigen for vaccine potency and standardization.
ssRNA Single-Stranded RNA:
RNA composed of one nucleotide strand, serving as the genome of many vaccine-targeted viruses and as a therapeutic platform.
SUB Single-Use Bioreactor:
A disposable culture vessel that reduces cleaning requirements and supports flexible production of cells, vectors, vaccines, and proteins.
SUS Single-Use System:
Disposable process equipment such as bags, tubing, connectors, and filters used to increase manufacturing flexibility and reduce cross-contamination risk.
SUSAR Suspected Unexpected Serious Adverse Reaction:
A serious reaction considered related to an investigational product and inconsistent with existing reference safety information.
T
TALEN Transcription Activator-Like Effector Nuclease:
An engineered genome-editing protein that combines sequence-specific DNA binding with targeted nuclease activity.
TCR T-Cell Receptor:
The receptor through which T cells recognize peptide antigens presented by major histocompatibility molecules.
TCR-T T-Cell Receptor-Engineered T-Cell Therapy:
A cellular therapy in which T cells are modified to express a selected receptor recognizing a tumor or disease-associated peptide.
TCID50 50% Tissue Culture Infectious Dose:
The quantity of virus required to infect half of inoculated tissue-culture units under defined assay conditions.
Tdap Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine:
A combination booster vaccine formulated for adolescents and adults, including use during pregnancy in many immunization programs.
TEAE Treatment-Emergent Adverse Event:
An event that begins or worsens after treatment initiation and is included in clinical safety analyses.
TFF Tangential Flow Filtration:
A membrane process used to concentrate products, exchange buffers, and separate components while fluid flows parallel to the membrane surface.
Th1 T Helper Type 1:
A helper T-cell response associated with cellular immunity and cytokines that support defense against intracellular pathogens.
Th2 T Helper Type 2:
A helper T-cell response associated with antibody production, eosinophilic responses, and selected vaccine immune profiles.
TLR Toll-Like Receptor:
An innate immune receptor that recognizes conserved molecular patterns and can be targeted by vaccine adjuvants.
TNF Tumor Necrosis Factor:
A potent inflammatory cytokine measured in immune-response studies and implicated in treatment-related inflammatory toxicities.
TPP Target Product Profile:
A strategic description of intended indications, populations, dosing, efficacy, safety, presentation, and differentiation that guides development decisions.
TSE Transmissible Spongiform Encephalopathy:
A group of prion diseases addressed through sourcing controls and risk assessments for human- or animal-derived materials.
TU Transducing Unit:
A functional measure of viral-vector particles capable of delivering genetic material to target cells.
U
UF/DF Ultrafiltration/Diafiltration:
Membrane operations used to concentrate a biological product and exchange or adjust its formulation buffer.
ULT Ultra-Low Temperature:
Storage conditions commonly around −80°C that are required for certain vaccines, vectors, starting materials, and biological samples.
USP United States Pharmacopeia:
The official U.S. compendium establishing public standards and test methods for medicines, ingredients, and biological products.
USP Upstream Processing:
The cell expansion, culture, fermentation, infection, or expression operations used to generate biological material before harvest and purification.
UTR Untranslated Region:
A non-protein-coding region of messenger RNA that can influence transcript stability, localization, and translation efficiency.
V
VAERS Vaccine Adverse Event Reporting System:
The U.S. national passive surveillance system that collects reports of health events occurring after vaccination.
VCN Vector Copy Number:
The average number of integrated vector copies per cell, a key quality and safety attribute for genetically modified cell products.
VE Vaccine Efficacy:
The proportional reduction in disease among vaccinated participants under controlled clinical-trial conditions.
VE Vaccine Effectiveness:
The reduction in disease associated with vaccination under real-world conditions, typically estimated through observational studies.
VFC Vaccines for Children:
A U.S. program that purchases and supplies recommended vaccines for eligible children who might otherwise lack access.
vg Vector Genome:
A physical measure of gene-therapy vector particles based on quantification of packaged genomic sequences.
VHP Vaporized Hydrogen Peroxide:
A gaseous decontamination agent used for isolators, rooms, transfer chambers, and other controlled manufacturing spaces.
VIS Vaccine Information Statement:
A U.S. document explaining vaccine benefits and risks that must be provided for covered vaccines before administration.
VLP Virus-Like Particle:
A noninfectious structure that resembles a virus but lacks a complete replicating genome, enabling strong antigen presentation in vaccines.
VPD Vaccine-Preventable Disease:
An infectious disease for which vaccination can substantially reduce incidence, severity, complications, or transmission.
VSD Vaccine Safety Datalink:
A U.S. collaborative surveillance system using electronic health data to conduct active vaccine-safety studies.
VSV Vesicular Stomatitis Virus:
An enveloped RNA virus engineered as a vaccine and oncolytic-vector platform.
VVM Vaccine Vial Monitor:
A heat-sensitive label that changes appearance according to cumulative thermal exposure and helps determine whether a vaccine remains usable.
W
WCB Working Cell Bank:
A qualified cell stock derived from a master cell bank and used to initiate routine manufacturing batches.
WFI Water for Injection:
A highly purified compendial water grade used in manufacturing parenteral products and cleaning critical process equipment.
WHO World Health Organization:
The United Nations health agency that develops vaccine policy, technical standards, prequalification programs, and global immunization guidance.
WPRE Woodchuck Hepatitis Virus Post-Transcriptional Regulatory Element:
A vector element used to enhance transgene RNA processing, stability, and expression in some gene-delivery constructs.
WSL Working Seed Lot:
A production seed derived from a master seed lot and used to initiate routine vaccine-manufacturing batches.
X
XMuLV Xenotropic Murine Leukemia Virus:
A murine retrovirus used in viral-safety evaluations and monitored as a potential adventitious contaminant of certain cell substrates.
Z
ZFN Zinc Finger Nuclease:
An engineered genome-editing protein combining sequence-specific zinc-finger DNA binding with targeted nuclease activity.